Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novadel’s NitroMist Application Moves Forward With Complete Response

This article was originally published in The Pink Sheet Daily

Executive Summary

The nitroglycerin NDA has an updated user fee date in early November.

You may also be interested in...



NovaDel Set To Submit Zolpidem Oral Spray In Second Half 2007

Firm also moves up timeline on sumatriptan oral spray submission to first half of 2008.

NovaDel Set To Submit Zolpidem Oral Spray In Second Half 2007

Firm also moves up timeline on sumatriptan oral spray submission to first half of 2008.

NovaDel's NitroMist Is "Approvable" At FDA

The company expects full approval for the 505(b)(2) product following completion of manufacturing validation commitments. Par will co-promote the product, which administers nitroglycerine to the oral mucosa.

Related Content

Topics

UsernamePublicRestriction

Register

PS064234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel